ArticleJournal of diabetes investigation2026
Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionIdentifying patient characteristics predictive of treatment response is crucial for optimizing type 2 diabetes outcomes. Using data from three phase 2/3 imeglimin trials in Japan, this analysis applied machine learning to determine characteristics associated with HbA1c improvement.
methodsRegression tree and random forest methods identified baseline characteristics predictive of HbA1c improvement. Partial dependence plots (PDP) visualized the relationship between HbA1c change and continuous variables deemed important by Boruta.
resultsFor monotherapy, key predictors were baseline HbA1c, hypertension, smoking, type 2 diabetes duration, body mass index (BMI), low-density lipoprotein-cholesterol (LDL-C), metabolic syndrome, and estimated glomerular filtration rate. Nonsmokers with HbA1c ≥8.35% and LDL-C < 3.26 mmol/L at baseline showed the greatest improvement in HbA1c (-1.24%). Random forest analysis and Boruta identified baseline HbA1c, BMI, fatty liver index, smoking, and hypertension as significant predictors of HbA1c improvement. PDPs identified a positive correlation between higher baseline HbA1c, and a negative correlation between BMI and fatty liver index, and HbA1c improvement. For imeglimin add-on to insulin therapy, key predictors were BMI, age, LDL-C, type 2 diabetes duration, systolic blood pressure, and alanine transaminase (ALT). Patients with BMI <25.9, LDL-C < 2.68 mmol/L, and ALT <21 U/L showed the greatest HbA1c improvement (-1.48%). Random forest analysis and Boruta confirmed BMI, age, and LDL-C as significant predictors. PDPs identified a positive correlation between older age, and a negative correlation between higher BMI and LDL-C, and HbA1c improvement.
conclusionsMachine learning effectively identified baseline characteristics predictive of HbA1c response to imeglimin, supporting the potential for personalized type 2 diabetes treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.